Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Study Summary

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents

Conditions

Locally Advanced or Metastatic ER+ HER2- Breast Cancer Locally Advanced or Metastatic Castration-resistant Prostate Cancer Locally Advanced or Metastatic Non-small Cell Lung Cancer

Interventions / Drugs

PF-07248144 Fulvestrant Letrozole Palbociclib PF-07220060 PF-07850327, ARV-471, vepdegestrant

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment320 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.190090+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.